Acoart SCB SFA: Sirolimus Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis

Last updated: October 16, 2023
Sponsor: Acotec Scientific Co., Ltd
Overall Status: Active - Recruiting

Phase

N/A

Condition

Atherosclerosis

Claudication

Peripheral Arterial Occlusive Disease

Treatment

Sirolimus-eluting balloon catheter

Paclitaxel-eluting balloon catheter

Clinical Study ID

NCT04982367
Acoart SCB SFA
  • Ages 18-80
  • All Genders

Study Summary

A prospective randomized trial designed to compare the efficacy and safety of Sirolimus coated balloon (SCB) versus paclitaxel coated balloon (DCB) in the treatment of femoropopliteal artery stenosis

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥18 years old and ≤80 years old
  • Had lower extremity arterial occlusive diseases, and Rutherford classification is 2-5
  • SFA and/or popliteal artery had severe stenosis (stenosis degree ≥70%) or occlusion.
  • The length of target lesion less than 20 cm
  • Subject (or legal guardian) understands the study requirements and procedures andprovides written Informed Consent before any study tests or procedures are performed

Exclusion

Exclusion Criteria:

  • The plasma creatinine level is higher than 150 umol/L
  • Thrombolysis or thrombectomy is required
  • There are more than 2 lesion need to treat in the target vessel.
  • The patient had underwent lower-limb arterial surgery or thrombolysis on the targetlimb within 6 weeks.
  • The target lesion had residual stenosis>30% or flow-limit dissection afterpre-dilatation.
  • The patient had outflow less than 1 vessel
  • The lesion located in a stent.
  • Patient has a known allergy to aspirin, clopidogrel, heparin, paclitaxel, sirolimus orcontrast medium that cannot be adequately pre-medicated.
  • Women who are pregnant or breast-feeding.
  • The subjects have participated in other drug property studies or device studies thathave not yet completed the main end point.
  • Patient has life expectancy of less than 12 months.
  • The investigator think the patient is not suitable for participation in the clinicaltrial.

Study Design

Total Participants: 166
Treatment Group(s): 2
Primary Treatment: Sirolimus-eluting balloon catheter
Phase:
Study Start date:
December 08, 2021
Estimated Completion Date:
July 31, 2024

Connect with a study center

  • Chinese PLA General Hospital

    Beijing, Beijing 100039
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.